The results demonstrated the safety of pelareorep at 3 × 108 TCID50 doses, as well as the safety of intravenous and repeat dosing, and the reduction in PSA levels (from 100 to 50 ng/mL) in a patient with PCa indicative of potential efficacy [239]. This evidence concerns the gene KLK3 and posterior cortical atrophy.